Literature DB >> 30792212

TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies.

Marianna B Ruzinova1, Yi-Shan Lee1, Eric J Duncavage1, John S Welch2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30792212      PMCID： PMC6669137          DOI： 10.3324/haematol.2018.205302

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

Authors:  Leonie Saft; Mohsen Karimi; Mehran Ghaderi; András Matolcsy; Ghulam J Mufti; Austin Kulasekararaj; Gudrun Göhring; Aristoteles Giagounidis; Dominik Selleslag; Petra Muus; Guillermo Sanz; Moshe Mittelman; David Bowen; Anna Porwit; Tommy Fu; Jay Backstrom; Pierre Fenaux; Kyle J MacBeth; Eva Hellström-Lindberg
Journal:  Haematologica       Date:  2014-03-28       Impact factor: 9.941

Review 2.  Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue.

Authors:  Kelly B Engel; Helen M Moore
Journal:  Arch Pathol Lab Med       Date:  2011-05       Impact factor: 5.534

3.  Oncogenic forms of p53 inhibit p53-regulated gene expression.

Authors:  S E Kern; J A Pietenpol; S Thiagalingam; A Seymour; K W Kinzler; B Vogelstein
Journal:  Science       Date:  1992-05-08       Impact factor: 47.728

4.  Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.

Authors:  William Blum; Ramiro Garzon; Rebecca B Klisovic; Sebastian Schwind; Alison Walker; Susan Geyer; Shujun Liu; Violaine Havelange; Heiko Becker; Larry Schaaf; Jon Mickle; Hollie Devine; Cheryl Kefauver; Steven M Devine; Kenneth K Chan; Nyla A Heerema; Clara D Bloomfield; Michael R Grever; John C Byrd; Miguel Villalona-Calero; Carlo M Croce; Guido Marcucci
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

5.  TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.

Authors:  Frank G Rücker; Richard F Schlenk; Lars Bullinger; Sabine Kayser; Veronica Teleanu; Helena Kett; Marianne Habdank; Carla-Maria Kugler; Karlheinz Holzmann; Verena I Gaidzik; Peter Paschka; Gerhard Held; Marie von Lilienfeld-Toal; Michael Lübbert; Stefan Fröhling; Thorsten Zenz; Jürgen Krauter; Brigitte Schlegelberger; Arnold Ganser; Peter Lichter; Konstanze Döhner; Hartmut Döhner
Journal:  Blood       Date:  2011-12-20       Impact factor: 22.113

6.  Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia.

Authors:  Kathy L McGraw; Johnny Nguyen; Rami S Komrokji; David Sallman; Najla H Al Ali; Eric Padron; Jeffrey E Lancet; Lynn C Moscinski; Alan F List; Ling Zhang
Journal:  Haematologica       Date:  2016-04-14       Impact factor: 9.941

7.  TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.

Authors:  Austin G Kulasekararaj; Alexander E Smith; Syed A Mian; Azim M Mohamedali; Pramila Krishnamurthy; Nicholas C Lea; Joop Gäken; Coralie Pennaneach; Robin Ireland; Barbara Czepulkowski; Sabine Pomplun; Judith C Marsh; Ghulam J Mufti
Journal:  Br J Haematol       Date:  2013-01-09       Impact factor: 6.998

8.  Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.

Authors:  Amanda F Cashen; Gary J Schiller; Margaret R O'Donnell; John F DiPersio
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

9.  p53 flow cytometry evaluation in leukemias: correlation to factors affecting clinical outcome.

Authors:  Geraldo Barroso Cavalcanti; Marcos Antonio Mauricio Scheiner; Eliane Pereira Simões Magluta; Flavia da Cunha Vasconcelos; Claudete Esteves Klumb; Raquel Ciuvalschi Maia
Journal:  Cytometry B Clin Cytom       Date:  2010-07       Impact factor: 3.058

10.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

Authors:  Timothy J Ley; Christopher Miller; Li Ding; Benjamin J Raphael; Andrew J Mungall; A Gordon Robertson; Katherine Hoadley; Timothy J Triche; Peter W Laird; Jack D Baty; Lucinda L Fulton; Robert Fulton; Sharon E Heath; Joelle Kalicki-Veizer; Cyriac Kandoth; Jeffery M Klco; Daniel C Koboldt; Krishna-Latha Kanchi; Shashikant Kulkarni; Tamara L Lamprecht; David E Larson; Ling Lin; Charles Lu; Michael D McLellan; Joshua F McMichael; Jacqueline Payton; Heather Schmidt; David H Spencer; Michael H Tomasson; John W Wallis; Lukas D Wartman; Mark A Watson; John Welch; Michael C Wendl; Adrian Ally; Miruna Balasundaram; Inanc Birol; Yaron Butterfield; Readman Chiu; Andy Chu; Eric Chuah; Hye-Jung Chun; Richard Corbett; Noreen Dhalla; Ranabir Guin; An He; Carrie Hirst; Martin Hirst; Robert A Holt; Steven Jones; Aly Karsan; Darlene Lee; Haiyan I Li; Marco A Marra; Michael Mayo; Richard A Moore; Karen Mungall; Jeremy Parker; Erin Pleasance; Patrick Plettner; Jacquie Schein; Dominik Stoll; Lucas Swanson; Angela Tam; Nina Thiessen; Richard Varhol; Natasja Wye; Yongjun Zhao; Stacey Gabriel; Gad Getz; Carrie Sougnez; Lihua Zou; Mark D M Leiserson; Fabio Vandin; Hsin-Ta Wu; Frederick Applebaum; Stephen B Baylin; Rehan Akbani; Bradley M Broom; Ken Chen; Thomas C Motter; Khanh Nguyen; John N Weinstein; Nianziang Zhang; Martin L Ferguson; Christopher Adams; Aaron Black; Jay Bowen; Julie Gastier-Foster; Thomas Grossman; Tara Lichtenberg; Lisa Wise; Tanja Davidsen; John A Demchok; Kenna R Mills Shaw; Margi Sheth; Heidi J Sofia; Liming Yang; James R Downing; Greg Eley
Journal:  N Engl J Med       Date:  2013-05-01       Impact factor: 91.245
View more
  2 in total

1.  Decitabine salvage for TP53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy.

Authors:  Francesca Ferraro; Agata Gruszczynska; Marianna B Ruzinova; Christopher A Miller; Mary Elizabeth Percival; Geoffrey L Uy; Iskra Pusic; Meagan A Jacoby; Mathew J Christopher; Miriam Y Kim; Peter Westervelt; Amanda F Cashen; Mark A Schroeder; John F DiPersio; Camille N Abboud; Lukas D Wartman; Feng Gao; Daniel C Link; Timothy J Ley; John S Welch
Journal:  Haematologica       Date:  2022-07-01       Impact factor: 11.047

2.  Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases.

Authors:  Hong Fang; Sa A Wang; Joseph D Khoury; Siba El Hussein; Do Hwan Kim; Mehrnoosh Tashakori; Zhenya Tang; Shaoying Li; Zhihong Hu; Fatima Zahra Jelloul; Keyur P Patel; Timothy J McDonnell; Tapan Kadia; L Jeffrey Medeiros; Wei Wang
Journal:  Haematologica       Date:  2022-09-01       Impact factor: 11.047
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.